
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is well-positioned for future growth with its strong and diverse product portfolio focused on aortic solutions, expansion into key international markets, and consistent revenue and margin growth. While the company does face some risks, such as non-North American revenue and regulatory challenges, its strong financials and positive outlook make it a favorable investment opportunity for analysts. Its recent 1Q26 results showed a slight beat in top-line revenue but a lowered full-year guidance due to temporary challenges in international stent graft sales and slower initial stocking orders for a new product. However, these issues are expected to improve throughout the year and do not affect the overall long-term potential of the company.
Bears say
Artivion is facing significant challenges in the near future, with guidance resets and potential disruptions due to the delayed launch of the NEXUS product. While it is positioned well for long-term growth and has a strong base business, the recent financials show underwhelming performance with a revenue beat but a missed consensus on EBITDA and lowered guidance for 2026. The company is also facing significant debt and earnout payments for its recently acquired products, which will likely impact its ability to generate free cash flow in the short term. Additionally, management has identified barriers to adoption for its products, which may delay the commercial success of its new launches.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares